Closed tender

NHS Pharmaceuticals 2017_2

Details

Value
GBP 45,850,500
Topic
Pharmaceutical products
Published
18 January 2018
Submission
26 January 2018

Tender description

NHS Pharmaceuticals 2017_2. Period of framework agreement: The total maximum duration of the framework agreement to be no more than 36 months. Potential periods of call-offs under the framework agreement: CESW regions: 1.8.2018 to 28.2.2019 (7 months). NWLN regions: 1.8.2018 to 31.7.2019 (12 months). LSNE regions: 1.8.2018 to 31.1.2020 (18 months). Products on the framework include (but are not necessarily limited to): Abacavir, Abiraterone, Anidulafungin, Atovaquone, Bosentan, Ciclesonide, Drospirenone/Ethinylestradiol, Enfurvitide, Ethinylestradiol/Norelgestromin, Exenatide, Ezetimibe, Iloprost, Ivabradine, Mycophenolic acid, Nitisinone, Olopatadine, Oseltamivir, Parecoxib, Pegfilgrastim, Pegvisomant, Pregabalin, Tadalafil, Tenofovir, Tigecycline, Valproic acid, Velaglucerase. Details of regions, presentation sizes and volumes are within the tender document set.

Timeline

  1. Completed: Tender published18 January 2018
    Current notice
  2. Completed: Submission date26 January 2018

About the buyer

NHS England is a public sector buyer in United Kingdom publishing tenders and awards on Stotles. Explore their procurement activity and find more opportunities like this one.

Relevant CPV codes

  • 33600000 · Pharmaceutical products

AI insights

  • Is there a preferred supplier?
  • What are the buyers pain points?
  • What has the buyer previously procured?
  • What are the key requirements?
Sign-up to enrich

Decision makers

Connect with the people behind this procurement.

Contact nameJob titlePhone numberWork email
Head of Procurement+44 •••• ••••••
Commercial Director+44 •••• ••••••
Procurement Manager+44 •••• ••••••
Category Lead+44 •••• ••••••
Senior Buyer+44 •••• ••••••
Contracts Manager+44 •••• ••••••

Win more public sector contracts

Track every UK and Ireland tender in one place — set up alerts, find decision-makers, and never miss an opportunity.